None listed
Conditions
Interventions
Dietary Supplement : The intervention group was divided into two groups based on whether or not they took the test food, NXP032 (vitamin C, Aptamin C320 complex). The test group took one tablet (36.05
Sponsors
NEXMOS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those aged 19 years or older and 75 years or younger. 2) Those with a peripheral blood leukocyte count of 4x10^3 cells/µL or higher and less than 8x10^3 cells/µL as measured at Visit 1. 3) Those with a Perceived Stress Scale (PSS) score of 16 or higher. 4) Those who meet at least one of the following criteria: ? Those who have had two or more upper respiratory infections* within the year prior to Visit 1 *{Common Cold, acute tonsillitis, acute pharyngitis, acute laryngitis, acute rhinitis, etc.} ? Those who have had stomatitis two or more times within the year prior to Visit 1 ? Those who have had Herpes Zoster infection within the year prior to Visit 1 ? Those who have had three or more episodes of uncomplicated cystitis within the year prior to Visit 1 or two or more episodes of uncomplicated cystitis within the six months prior to Visit 1 ? Those who have experienced chronic fatigue symptoms (unexplained severe fatigue lasting more than three months, decreased concentration, memory loss, sleep disturbance, etc.) within the six months prior to Visit 1 5) A person who agrees to participate in the human application test and completes a written consent form (Informed Consent Form) before the human application test begins.
Exclusion criteria
Exclusion criteria: 1) Those currently receiving treatment for clinically significant acute or chronic cardiovascular, endocrine (e.g., thyroid disease), immune, respiratory, hepatobiliary, renal, urinary, nervous, musculoskeletal, psychiatric, infectious, hematological, or oncological diseases (however, participation in the study may be permitted at the discretion of the principal investigator, taking into account the subject's condition). 2) Hypertensive patients (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg, measured after 10 minutes of rest for human application test subjects). 3) Diabetic patients with a fasting blood sugar level =126 mg/dL or taking antidiabetic medication (oral hypoglycemic agents, insulin, etc.). 4) Those who have received any vaccines (e.g., influenza, coronavirus, shingles, etc.) within 3 months of Visit 1. 5) Those with diseases that may affect the immune response, such as adult asthma or rhinitis. 6) Those who have donated whole blood within two months of Visit 1 or have donated apheresis within four weeks. 7) Those with AST (GOT) or ALT (GPT) levels three times or more the upper limit of normal for the testing institution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NK cell activity | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokines (IFN-?, TNF-a, IL-2, Granzyme A, Granzyme B, Perforin, Granulysin) | — |
Countries
Korea, Republic of
Contacts
Public ContactJihyun Kim
NEXMOS
Outcome results
None listed